Telix shares surge as much as 14% after its most advanced cancer therapy candidate passes phase III safety and dosimetry hurdles Clarity says it will achieve the targeted 220 patients for its prostate ...
The news: Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591. Shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results